Mediate Tumor Rejection Cutting Edge: IL-10-Producing CD4+ T Cells

Benjamin M. Segal, Deborah D. Glass and Ethan M. Shevachhttp://www.jimmunol.org/content/168/1/1J Immunol€2002; 168:1-4; ;Referenceshttp://www.jimmunol.org/content/168/1/1.full#ref-list-1This article cites 31 articles, 17 of which you can access for free at: Subscriptionshttp://jimmunol.org/subscriptionsInformation about subscribing to The Journal of Immunology is online at: Permissionshttp://www.aai.org/ji/copyright.htmlSubmit copyright permission requests at: Email Alertshttp://jimmunol.org/cgi/alerts/etocReceive free email-alerts when new articles cite this article. Sign up at:

[1]  S. Rosenberg,et al.  Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. , 1999, Journal of immunotherapy.

[2]  M. Lotze,et al.  Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. , 1996, Journal of immunology.

[3]  N. Romani,et al.  High Level IL-12 Product ion by Murine Dendrit ic Cells : Upregulation via MHC Class II and CD 40 Molecules and Downregulat ion by IL-4 and IL-10 By , 2003 .

[4]  F. Lemonnier,et al.  An HLA-A2 polyepitope vaccine for melanoma immunotherapy. , 1999, Journal of immunology.

[5]  M. Bar‐eli,et al.  Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[6]  E. Maxwell,et al.  Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism , 1996, The Journal of experimental medicine.

[7]  M. Malkin.  Therapy of malignant astrocytoma. , 1995, Cancer investigation.

[8]  R. Locksley,et al.  Altered Immune Responses in Interleukin 10 Transgenic Mice , 1997, The Journal of experimental medicine.

[9]  T. Mosmann,et al.  Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoadsorbent assay. , 1990, Journal of immunology.

[10]  R. Kastelein,et al.  IL‐10 enhances NK cell proliferation, cytotoxicity and production of IFN‐γ when combined with IL‐18 , 1999, European journal of immunology.

[11]  K. Okumura,et al.  Selective expression of interleukin-10 gene within glioblastoma multiforme , 1994, Brain Research.

[12]  S. Rosenberg,et al.  Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. , 1996, Journal of immunology.

[13]  C. Melief,et al.  Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors , 1998, The Journal of experimental medicine.

[14]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[15]  Hervé Groux,et al.  A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , 1997, Nature.

[16]  R. Dorsey,et al.  Expression of the Chemokines IP-10 and Mig in IL-10 Transduced Tumors , 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[17]  D. Pardoll,et al.  In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression , 1994, The Journal of experimental medicine.

[18]  A. Sher,et al.  In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. , 1996, Journal of immunology.

[19]  A. Fulton,et al.  Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. , 1997, Cellular immunology.

[20]  H. Maguire,et al.  Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. , 1999, Cancer research.

[21]  H. Saito,et al.  Staining of interleukin‐10 predicts clinical outcome in patients with nasopharyngeal carcinoma , 1999, Cancer.

[22]  T. Tanimoto,et al.  Simultaneous exposure to interleukin-18 and interleukin-10 in vitro synergistically augments murine spleen natural killer cell activity , 1999, Cancer Immunology, Immunotherapy.

[23]  Polly Matzinger,et al.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.

[24]  P. Musiani,et al.  Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. , 1995, Journal of immunology.

[25]  E. Shevach,et al.  IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. , 1992, Journal of immunology.

[26]  J. Laterra,et al.  IL-10 gene transfer to intracranial 9L glioma: tumor inhibition and cooperation with IL-2 , 1998, Journal of Neuroimmunology.

[27]  K. Rajewsky,et al.  Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.

[28]  M. Roncarolo,et al.  A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. , 1999, Journal of immunology.

[29]  E. Shevach,et al.  An Interleukin (IL)-10/IL-12 Immunoregulatory Circuit Controls Susceptibility to Autoimmune Disease , 1998, The Journal of experimental medicine.

[30]  H. Joo,et al.  Inhibition of interleukin-10 (IL-10) production from MOPC 315 tumor cells by IL-10 antisense oligodeoxynucleotides enhances cell-mediated immune responses , 2000, Cancer Immunology, Immunotherapy.

[31]  J. Banchereau,et al.  Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells , 1994, The Journal of experimental medicine.

[32]  R. Coffman,et al.  Interleukin-10 and the interleukin-10 receptor. , 2001, Annual review of immunology.